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Background: The administration of cytosine arabinoside (CA) by continuous rate infusion 14 
(CRI) at time of diagnosis has been shown to improve the 3-month survival of dogs diagnosed 15 
with meningoencephalomyelitis of unknown origin (MUO), compared to subcutaneous (SC) 16 
administration. The benefit of administering subsequent sequential CA SC injections is 17 
unknown. This study compares the outcomes of a CA CRI protocol with (CRI + SC group) or 18 
without (CRI group) follow-up CA SC injections; both groups received adjunctive 19 
prednisolone. 20 
Methods: Forty-two dogs diagnosed with MUO were recruited (CRI group) and compared 21 
with 41 historical control dogs (CRI + SC group) in a prospective, controlled clinical trial 22 
with 36 months follow-up. 23 
Results: Success rates were respectively 64.3% and 65% in the CRI and the CRI + SC groups 24 
at 40 weeks following diagnosis, and 32.5% and 35.9% at 36 months following diagnosis. 25 
Median time to relapse was 299 and 285 days for the CRI and the CRI + SC groups 26 
respectively. No statistical significant difference was found (p ≥ 0.05). 27 
Conclusion: No clear benefit was identified in the administration of subsequent sequential 28 
CA SC injections after the first administration of CA by CRI for the treatment of dogs 29 
diagnosed with MUO. 30 
 31 
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Meningoencephalomyelitis of unknown origin is a group of idiopathic, inflammatory central 36 
nervous system diseases of presumed immune-mediated origin, encompassing granulomatous 37 
meningoencephalomyelitis (GME), necrotizing meningoencephalomyelitis (NME) and 38 
necrotizing leukoencephalitis (NLE). This group of diseases is considered fatal if left 39 
untreated, but no consensus has yet been reached on the ideal treatment protocol of these 40 
dogs. Glucocorticoids are generally considered to be the mainstay of treatment, often in 41 
combination with additional immunosuppressive drugs.1 A popular treatment protocol for 42 
dogs diagnosed with MUO is the combination of CA with glucocorticoids tapered slowly over 43 
several months2-5. A clear improvement in survival at 3 months following diagnosis has been 44 
shown with the administration of CA at the time of diagnosis by CRI compared to SC 45 
delivery6. In this treatment protocol, subsequent SC CA injections are performed every few 46 
weeks (initially at 3-week intervals, and then less and less frequently over time) following the 47 
CRI for a total duration of 72 weeks (18 months). Because of the extended duration of the 48 
therapeutic regime and the 48 hour hospitalisation required for each cycle of CA therapy, this 49 
treatment protocol requires considerable time and financial commitment from the owner. The 50 
aim of this study was to assess the necessity of administering subsequent SC CA injections 51 
for the treatment of dogs with MUO following a single CRI of CA, by comparing the clinical 52 
outcome in a cohort of dogs receiving initial CA CRI without further regular cycles of CA 53 
with historical control data. Further outcome data is also presented from the historical control 54 
group. 55 
 56 





This study adds to data from a previous prospective treatment trial of the effect of oral 59 
prednisolone and CA administered by CRI followed by SC injections in dogs with MUO. 60 
Complete details of this study are described elsewhere.5,6 Dogs with MUO presented 61 
consecutively at the neurology department of Davies Veterinary Specialists between August 62 
2011 and August 2015 were recruited prospectively to form the CRI + SC.6 Dogs presented 63 
consecutively at the neurology department of Dovecote Veterinary Hospital between August 64 
2015 and July 2017 were then recruited prospectively to form the CRI treatment group. For 65 
both groups, following receipt of owner consent, dogs with a history of steroid administration 66 
prior to presentation were excluded from the study. Signalment and history were recorded, 67 
including the duration of clinical signs before investigations. Physical and neurological 68 
examinations were performed. Blood analysis including complete blood count, biochemistry, 69 
antibody titers to Neospora caninum and Toxoplasma gondii (indirect fluorescence antibody 70 
tests), MRI of the brain (0.4T magnet [Aperto MRI, Hitachi, Tokyo, Japan] for the CRI + SC 71 
group and 0.25T permanent magnet [Esaote VetMR Grande, Genova, Italy] for the CRI 72 
group) and cerebrospinal fluid (CSF) analysis (including a total nucleated cell count (TNCC), 73 
cytology and protein concentration) were also performed. Dogs were followed-up 74 
prospectively for at least 36 months following diagnosis and initiation of treatment. 75 
 76 
Diagnosis 77 
A presumptive diagnosis of MUO was based on guidelines of a previous study7. Dogs were 78 
considered to have MUO if they were older than 6 months, with evidence of single, multiple 79 
or diffuse intracranial abnormalities on MRI, CSF pleocytosis (TNCC > 5 cells/µL, 80 
erythrocyte count < 4000 cells/µL), > 50% mononuclear cells and an absence of antibodies 81 
against Neospora caninum and Toxoplasma gondii. Dogs with focal cortical abnormalities 82 




may represent a necrotizing form of MUO), as were those with the optic focal form of GME. 84 
The presence or absence of MRI features as single or multiple abnormalities, sulci 85 
effacement, rostral and/or caudal fossa involvement, contrast enhancement, mass effect, 86 
foramen magnum and/or trans-tentorial herniation were also determined for each case. 87 
Diagnosis for a relapse was made based on recurrence of initial clinical signs and when 88 
possible, repeated MRI of the brain and CSF analysis. 89 
 90 
Treatment 91 
All dogs were treated with a standard protocol of prednisolone, starting at immunosuppressive 92 
doses and then tapering progressively over 34 weeks, as well as an initial CRI of CA at the 93 
dose of 100mg/m2. The first 41 dogs then continued to receive sequential SC injections of CA 94 
at a dose of 50mg/m2 every 12h for 2 days (CRI + SC group), initially at 3-week intervals and 95 
then at a decreasing frequency for a total of 72 weeks (18 months), the 3-month survival 96 
outcome in this group has been reported previously6. The remaining 42 dogs did not receive 97 
any further CA administration (CRI group). Both treatment protocols are outlined in Figure 1. 98 
If a dog relapsed at any point during this treatment scheme, decisions on treatment were 99 
altered on an individual basis. As this was an accessional study, any dog with a diagnosis of 100 
MUO was immediately assigned to the CRI group and included in the results analysis, even if 101 
the CRI was unable to be commenced or completed (e.g. due to death). 102 
 103 
Outcome 104 
Treatment “success” was defined as sustained neurological improvement following initiation 105 
and completion of the standardized treatment protocol. All dogs with signs suggestive for 106 
recurrence or persistence of signs necessitating a change in the treatment plan were termed as 107 




their clinical signs and achieve sustained remission. All dogs that died or were euthanized 109 
following diagnosis were termed “dead” and included in the statistics and survival analysis.  110 
 111 
Primary outcome measures were the success, relapse and death rates for each treatment group. 112 
Those were assessed at 4 different timespans: at 34 weeks (completion of prednisolone 113 
treatment protocol), 40 weeks (6 weeks after prednisolone discontinuation), 72 weeks (end of 114 
the SC CA injections for the CRI + SC group) and 36 months following diagnosis. Repeat 115 
MRI and CSF were also performed at 3 months following diagnosis in 37/41 dogs of the CRI 116 
+ SC group and 36/42 dogs of the CRI group. 117 
 118 
Time to relapse was assessed as a secondary outcome measure over the 36-month study 119 
period. Median survival times were determined for the entire group of dogs and for the subset 120 
of dogs that could be followed up until death (related or not to MUO). 121 
 122 
Statistical analysis 123 
Baseline characteristics of dogs in the 2 groups were compared: categorical variables (sex, 124 
MRI features) were compared using a Fisher exact test, whereas continuous variables (age, 125 
delay to presentation, CSF TNCC, CSF protein concentration) were compared using a Mann-126 
Whitney test. Primary outcome measures were compared between both groups using a Fisher 127 
exact test, whereas time to relapse was compared using a Mann-Whitney test. Long-term 128 
survival analysis (> 36 months) was assessed with a Kaplan Meier survival curve as well as a 129 







A total of 83 dogs were recruited. Forty-one dogs were given sequential CA SC injections 134 
after the initial CA CRI (CRI + SC group) and acted as historical controls, a further 42 dogs 135 
were recruited prospectively and did not receive any CA injections following the initial CA 136 
CRI (CRI group). There was no significant difference in age at presentation, sex, delay to 137 
presentation or CSF analysis between the two groups (Table 1). As it has been shown 138 
previously that some MRI features at the time of diagnosis can have an impact on mortality5,6, 139 
these features were also compared and no significant difference was found between groups 140 
(Supplementary information files). Over the 36-month study period, 2 dogs from each group 141 
were lost to follow-up, at 270 and 472 days for the CRI + SC group and at 301 and 372 days 142 
for the CRI group. Those dogs were doing well at the time they were lost to follow-up, but 143 
were removed from the study calculations and statistics at their respective time points when 144 
lost to follow-up in order to avoid bias. Sample size therefore decreased to 40 dogs at 40 145 
weeks and 39 dogs at 72 weeks for the CRI + SC group, and 40 dogs at 72 weeks for the CRI 146 
group and remained constant thereafter until 36 months (Table 2). 147 
 148 
Primary outcome measures: success, relapse and death rates 149 
At 34 weeks (238 days), treatment success was seen in 28/42 dogs (66.7%) in the CRI group, 150 
and in 31/41 dogs (75.6%) in the CRI + SC group. Relapse was seen in 8 dogs (19%) in the 151 
CRI group and in 6 dogs (14.6%) in the CRI + SC group. Six dogs (14.3%) in the CRI group 152 
and 4 dogs (9.8%) in the CRI + SC group died as a consequence of their MUO. At 40 weeks 153 
(280 days), success rates reduced to 64.3% and 65% (27/42 and 26/40 dogs), and relapse rates 154 
were 21.4% and 25% (9/42 and 10/40 dogs) for the CRI and CRI + SC groups respectively. 155 
At 72 weeks (505 days), treatment success further decreased to 45% and 43.6% (18/40 and 156 
17/39) of dogs and relapse increased to 40% and 46.1% (16/40 and 18/39) of dogs in the CRI 157 




rates decreased to 32.5% and 35.9% (13/40 and 14/39 dogs), whereas 52.5% and 53.8% 159 
(21/40 and 21/39) of dogs had relapsed for the CRI and the CRI + SC groups respectively. All 160 
these values were compared and found not to be significantly different (p ≥ 0.05; Table 3). 161 
The last two dogs died between 5 to 6 months after diagnosis, so all dogs that were alive 6  162 
months (24 weeks) following diagnosis, (85% of dogs from the CRI group and 89.7% of dogs 163 
from the CRI + SC group) remained alive 36 months following diagnosis. No adverse effects 164 
were reported by owners.  165 
MRI and CSF abnormalities at three month follow-up were collected. Thirty-four of 37 (92%) 166 
surviving dogs in the CRI+ SC group had a normal MRI scan at 3 months, compared with 167 
32/36 (89%) surviving dogs in the CRI group (P = 0.71). In addition, CSF was normal in a 168 
similar proportion of dogs from each group (36/37 dogs in CA + SC, 97% versus 34/36 dogs 169 
in CRI, 94%; P = 0.61). 170 
 171 
Secondary outcome measures: time to relapse and survival times 172 
Median time to relapse was 299 days (range: 82-1024 days) for the CRI group and 285 days 173 
(range: 97-1081 days) for the CRI + SC group (p = 0.88). At 36 months, 21 dogs from each 174 
group were receiving a long-term low dose of prednisolone in order to maintain remission of 175 
clinical signs, which represented 61.8% of the surviving population in the CRI group, and 176 
60% of the surviving population in the CRI + SC group. 177 
 178 
 179 
A Kaplan Meier survival curve was generated to assess long-term survival (Figure 2). In total, 180 
16/42 dogs (38.1%) from the CRI group and 15/41 dogs (36.6%) from the CRI + SC could be 181 
followed long-term until their death (whether related to their MUO or not); the remaining 182 




days (range: 0-2081 days) for the CRI group and 1745 days (range 0-3045 days) for the CRI + 184 
SC group. This was not significantly different (p = 0.17). As ≥ 85% of the dogs (34/40 dogs 185 
in the CRI group and 35/39 dogs in the CRI + SC group) were still alive at the end of the 186 
study (36 months), the median survival time could not be assessed in either of the two groups, 187 
but as the median follow-up time in both groups was >1095 days, the median survival time 188 
will be at least as long.  189 
 190 
DISCUSSION 191 
In this study, no significant difference was found in the medium to long-term outcome of dogs 192 
with MUO treated with an initial CA CRI with or without sequential follow-up CA SC 193 
injections. Even though a small difference in the success and relapse rates seemed to be 194 
present between both treatment protocols at 34 weeks, those rates became equivocal at 40 195 
weeks until 36 months following diagnosis (Table 3). Median time to relapse was also 196 
comparable between both groups about 10 months following diagnosis, shortly after 197 
discontinuation of prednisolone therapy. About 85% of dogs in the CRI group and 90% of 198 
dogs in the CRI + SC group were alive and well at 36 months following diagnosis (the end 199 
point of this study), but ≥60% of dogs in both groups had to receive a small dose of 200 
prednisolone indefinitely to maintain remission. This raises the question of whether MUO 201 
dogs might benefit from receiving a very small dose of prednisolone in the longer-term 202 
instead of discontinuing at 34 weeks, but our study has not addressed this hypothesis. Relapse 203 
as a consequence of prednisolone dose reduction or withdrawal has been reported previously 204 
in 2 dogs4. One dog in this same study was found to relapse after discontinuation of the CA 205 
SC injections. None of the dogs in our study were found to relapse or die shortly after 206 





Ten dogs from this study died from their MUO: 6 dogs from the CRI group and 4 dogs in the 209 
CRI + SC group. It is important to note that 8 of these dogs (4 from each group, 10%) died 210 
within the first 5 days following diagnosis, which is in accordance to the previously reported 211 
finding that about 15% of dogs with MUO die shortly following diagnosis7,8. Two previous 212 
studies5,9 reported 33% and 26% of dogs died within 1 week of MUO diagnosis respectively, 213 
which is higher than the 1-week mortality rate of our study. A possible explanation is the 214 
exclusion of cases with hypointense lesions on the MRI (suggestive of necrotizing 215 
encephalitis) in our study, whereas these cases were included in the study by Cornelis et al9. 216 
These studies also have different treatment protocols with the main variance being the 217 
standardised delivery of CA via a CRI in the present study, something that has been shown to 218 
be superior6, versus the heterogeneous regime in the earlier papers consisting of prednisolone 219 
with subcutaneous CA5 or a combination of prednisolone with or without CA delivered 220 
predominantly subcutaneously. The remaining 2 dogs that died during the 36-month period of 221 
observation did so between 5 and 6 months following diagnosis. Spontaneous death in cases 222 
diagnosed with MUO might be due to progression of the disease with involvement of the 223 
brain1, and therefore likely represents an extremely aggressive form of relapse. All 10 dogs 224 
that died had multiple brain lesions, mass effect and trans-tentorial herniation, 9 had sulci 225 
effacement and 4 (3 from the CRI group and 1 from the CRI + SC group) had foramen 226 
magnum herniation at time of diagnosis. Those MRI findings have been identified as risk 227 
factors predicting mortality5,8. There was no statistical difference in the number of dogs with 228 
multiple brain abnormalities, sulci effacement, mass effect or foramen magnum herniation 229 
between the CRI and the CRI + SC groups. All dogs with available follow-up that were alive 230 





Several studies describe the use of a combination of CA and prednisolone for the treatment of 233 
dogs with MUO2-4,10. However, only one of those studies describes the use of a single CA 234 
CRI combined with prednisolone in 9 dogs10. A median survival time of 1063 days was 235 
reported in that study, which is similar to the median survival of the deceased dogs from our 236 
CRI group (1131 days), and similar or inferior to the median survival time of all our dogs (> 237 
1095 days). It is important to note that our median survival time of 1131 days is based only on 238 
the dogs that were followed until death (related to their MUO or not). Subsequently this likely 239 
underestimates the true median survival time of the dogs in our study if the observation period 240 
had been extended until the time of death of all dogs. Overall, these figures are comparable to 241 
the 26-1025 days median survival times found in the literature for various protocols 242 
combining prednisolone and CA1-6.  243 
 244 
CA CRI has been shown to be both pharmacokinetically12 and clinically6 superior to SC 245 
administration, due to the achievement of a consistent and prolonged plasma steady-state 246 
concentration believed to allow better CNS penetration of the drug6,10,12. CA is considered to 247 
be a safe therapy in dogs with MUO, with only minimal adverse effects reported in previous 248 
studies2-6,10. Localised alopecia, dermatitis, calcinosis cutis and deep pyoderma have been 249 
described in rare cases with the SC route of administration of CA3,13, whereas gastrointestinal 250 
toxicity and myelosuppression are more common with high doses (300-600mg/m2) of CA 251 
administered by CRI14,15. No adverse effects have been reported following a single CA CRI at 252 
the dose of 100-200mg/m2 6,10-12, which was also observed in the dogs of our study. 253 
 254 
One of the major limitations of this study is that none of the cases were histopathologically 255 
confirmed. We decided not to use post-mortem or invasive biopsy as a requirement for 256 




either because they died, or by performing an invasive biopsy which could increase the risks 258 
of morbidity and mortality. Consent for post-mortem analysis could unfortunately not be 259 
obtained for any of the dogs that died in this study. Second, the diagnosis of relapse was 260 
mainly based on the recurrence of clinical signs and response to treatment adaptation, with 261 
only a minority of dogs having a second MRI or CSF analysis to confirm. Even though 262 
response to treatment was seen in all cases, this argument cannot be used to confirm the 263 
suspected relapse due to the large spectrum of action of the prednisolone; therefore, some of 264 
the dogs termed as “relapses” may in reality have been suffering from a separate condition 265 
rather than having a true relapse. A third limitation includes the survival analysis, as not all 266 
dogs included in the Kaplan Meier curve died from their MUO as they often already had an 267 
advanced age. Finally, this study was neither blinded nor randomized, and the treatment 268 
protocols were performed at different time points. However, all other variables of this study 269 
were kept constant to minimize inaccuracies in the study results, and as both groups did not 270 
differ significantly in any of the criteria at the starting point, we are relatively confident that 271 
potential biases are limited. The one exception to this was the field strength of the MRI 272 
altered between groups but both magnets were low-field and this may have excluded the more 273 
mildly affected dogs from the CRI only group by failing to identify lesions on the MRI and 274 
hence artificially improve this treatment modality. However, the similarity of outcome with 275 
both treatment modalities would suggest this would not alter our conclusion. 276 
 277 
CONCLUSION 278 
This study did not show a significant difference in the medium to long-term prognosis of dogs 279 
with MUO treated with an initial CA CRI and adjunctive prednisolone protocol with or 280 
without sequential follow-up CA SC injections. The proposed treatment protocol is less time 281 




dogs appear to relapse, most of them shortly after discontinuation of the prednisolone, 283 
necessitating the need to resume this medication and maintaining a small long-term dosage to 284 
remain in remission. This finding raises the question of whether MUO dogs might benefit 285 
from receiving a very small dose of prednisolone in the longer-term instead of discontinuing 286 
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TABLES AND FIGURES 334 
Table 1 335 
Summary of qualitative and quantitative variables at first presentation for the dogs of each 336 








Number of dogs 42 41   
Sex 
 
Female 21 22  
0.83 
Male 21 19  
Age (months) 45 (8-111) 47 (7-116)  0.69 
Time to presentation (days) 3 (0-13) 2 (0-26)  0.41 
CSF TNCC (cells/microL) 39 (8-792) 35 (9-693)  0.64 
CSF protein concentration (mg/dL) 53 (19-112) 46 (16-98)  0.47 
CRI: constant rate infusion; CSF: cerebrospinal fluid; TNCC: total nucleated cell count 338 
 339 
Table 2 340 
Success, relapse and death rates of the dogs of each protocol group at 34 weeks (prednisolone 341 
discontinuation), 40 weeks (6 weeks after prednisolone discontinuation), 74 weeks (end of the 342 
cytosine arabinoside SC injections for the CRI + SC group) and 36 months follow-up. Dogs 343 
that were lost to follow-up (2 dogs for each group: at 301 and 372 days for the CRI group and 344 
at 270 and 472 days from the CRI + SC group) were removed at their respective time points 345 
when lost to follow-up. 346 
 CRI group 
Nb of dogs (%) 
CRI + SC group 
Nb of dogs (%) 
P Value 




Relapse 8/42 (19) 6/41 (14.6) 0.77 
Death 6/42 (14.3) 4/41 (9.8) 0.74 
40 weeks  
(10 months) 
Success 27/42 (64.3) 26/40 (65) 1 
Relapse 9/42 (21.4) 10/40 (25) 0.80 
Death 6/42 (14.3) 4/40 (10) 0.74 
72 weeks  
(18 months) 
Success 18/40 (45) 17/39 (43.6) 1 
Relapse 16/40 (40) 18/39 (46.1) 0.65 
Death 6/40 (15) 4/39 (10.3) 0.74 
36 months Success 13/40 (32.5) 14/39 (35.9) 0.81 
Relapse 21/40 (52.5) 21/39 (53.8) 1 
Death 6/40 (15) 4/39 (10.3) 0.74 
Nb = number 347 
 348 
Figure 1 349 
Treatment protocol for dogs with meningoencephalomyelitis of unknown origin treated 350 
with a cytosine arabinoside constant rate infusion with (CA CRI + SC protocol) or without 351 
(CA CRI protocol) subsequent subcutaneous injections. Both groups received adjunctive 352 
prednisolone. A cycle refers to 4 SC injections, 12 hours apart. CA: cytosine arabinoside; 353 
CRI: constant rate infusion; q12h: twice daily; q24h: once daily; q48h: every other day; 354 
q72h: one in three days. 355 
 356 
Figure 2 357 
Kaplan Meier survival curve on long-term (> 36 months) follow-up of dogs diagnosed 358 




prednisolone and cytosine arabinoside constant rate infusion with (A) or without (B) 360 
subsequent subcutaneous injections. 361 
